Bela B.

Pfizer Inc. ( PFE - Analyst Report ) recently presented data on its chronic myeloid leukemia (CML) candidate, bosutinib. Read More

NEW YORK , Nov. 29, 2010 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando , December 4-7 .  Key highlights include results from a Phase 3 study, called the BELA ( B osutinib E fficacy and safety in chronic myeloid L eukemi A ) study, involving bosutinib for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).(1) The company will also present Phase 2 data from inotuzumab ozogamicin (CMC-544) for the treatment of B-cell Non-Hodgkin lymphoma (NHL).(2) These presentations underscore the company's commitment to advancing new treatments for patients living with various hematologic malignancies, which represent the second leading cause of cancer death.(3) (Logo:   http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) Pfizer also announced that it would initiate an open-label, randomized, Phase 3 study, Study B1931008, of inotuzumab ozogamicin administered in combination with rituximab compared to defined investigator's choice therapy in subjects with relapsed or refractory CD22-positive aggressive NHL who are not candidates for intensive high-dose chemotherapy.(4) This study will be open and enrolling in early 2011. Read More